LBPH News and Press, Longboard Pharmaceuticals Inc. From 05/22/23

2023-05-22 16:29:06 ET Summary Longboard looks like an intriguing play within the biotech sector. The company was spun out of Arena Pharmaceuticals in 2020 - Arena was subsequently acquired by Pfizer in a $6.7bn deal. Arena's lead candidate Etrasimod was an S1P Modulator indic...

LP352 Phase 1b/2a PACIFIC Study topline data expected in fourth quarter 2023 LP659 IND submitted to FDA after incorporating input from a pre-IND meeting; Phase 1 initiation of first in-human clinical study on track for second quarter 2023, with Phase 1 topline single-ascending dose data e...

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that Brandi Roberts, Longboard’s Chief Financial Officer, will present at the 22nd Annual Needham Vi...

SAN DIEGO and GAINESVILLE, Ga., April 05, 2023 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal CDMO”; NASD: SCTL ), a contract development and manufacturing organization (CDMO), today announced that it has been selected by Longboard Pharmaceuticals, Inc. (NASD: ...

2023-03-28 17:27:17 ET Gainers: Arcturus Therapeutics ( ARCT ) +15% . lululemon athletica ( LULU ) +11% . Fate Therapeutics ( FATE ) +5% . Kezar Life Sciences ( KZR ) +5% . Longboard Pharmaceuticals ( LBPH ) +4% . Losers: ...

Longboard Pharmaceuticals, Inc. (LBPH) Q4 2022 Results Earnings Conference Call March 2, 2023, 04:30 PM ET Company Participants Brandi Roberts - Executive Vice President and Chief Financial Officer Kevin Lind - President and Chief Executive Officer Randall Kaye - Execu...

Longboard Pharmaceuticals press release ( NASDAQ: LBPH ): FY GAAP EPS of -$2.56 beats by $0.03 . Co currently estimates 2023 operating expenses in the $57.0 to $63.0 million range. For further details see: Longboard Pharmaceuticals reports FY 2022 results

LP352 Phase 1b/2a PACIFIC Study remains on track to complete enrollment in the first half of 2023, with topline data expected in the second half of 2023 LP659 Phase 1 initiation of first in-human clinical study on track for first half of 2023, with Phase 1 topline single-ascending dose (S...

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it plans to release 2022 financial results and provide a corporate update on March 2, 2023. The Compan...

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the closing of its previously announced underwritten public offering of 5,750,000 shares of its voting common...